LEXINGTON, Mass., June 4 -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV - News) today announced that based on a recent discussion with the U.S. Food and Drug Administration (FDA) regarding the NDA ...
LEXINGTON, Mass., June 4 Indevus Pharmaceuticals, Inc.(Nasdaq: IDEV) today announced that based on a recent discussion with the U.S.Food and Drug Administration (FDA) regarding the NDA filing for ...
Indevus is facing a major setback in its efforts to gain approval for Nebido. The drug treats male hypogonadism, a condition in which the testicles fail to produce enough testosterone. Indevus said it ...
BANGALORE, June 4 (Reuters) - Indevus Pharmaceuticals Inc's injectable testosterone drug's approval may be delayed by two years, as U.S. health regulators are expected to ask for more safety data, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results